Information about latest EMVO’s communication regarding the impact of Brexit and the Northern Ireland Protocol in the EMVS

EMVO has been working to manage the implications of Brexit (the UK’s departure from the EU Internal Market rules) for the EMVS and its users. This was undertaken in close collaboration with concerned authorities and stakeholders, including the European Commission, as well as the most impacted National Medicines Verification Organisations (NMVOs).

At the end of September 2020, the EMVO Board decided that the existing UK system will remain connected and will become the UKNI MVS accessible for Northern Ireland (NI) End-Users from 1 January 2021.

As it stands, from 1 January 2021, the UK will no longer participate in the EU Internal Market, and FMD legislation will no longer apply in Great Britain (England, Scotland, Wales, the Channel Islands, and the Isle of Man). Northern Ireland will remain in the EU Internal Market, and therefore, FMD legislation will continue to apply in that region of the UK.

UK medicine packs released in the EU Internal Market prior to 1 January 2021 (legacy packs) can continue to be verified and decommissioned in the EMVS and require no additional action by On-Boarding Partners.

For more information please visit